{"id":"NCT01682876","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","officialTitle":"A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-07","primaryCompletion":"2013-07-02","completion":"2014-05-30","firstPosted":"2012-09-11","resultsPosted":"2014-10-06","lastUpdate":"2019-06-14"},"enrollment":715,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease","Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"MenACWY-CRM","otherNames":[]}],"arms":[{"label":"2 through 5 years (1 Vac) MenACWY-CRM 1","type":"PLACEBO_COMPARATOR"},{"label":"2 through 5 years (2 Vac) MenACWY-CRM 2","type":"ACTIVE_COMPARATOR"},{"label":"6 through 10 years (1 Vac) MenACWY-CRM 3","type":"PLACEBO_COMPARATOR"},{"label":"6 through 10 years (2 Vac) MenACWY-CRM 4","type":"ACTIVE_COMPARATOR"}],"summary":"This study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine, given 2 months apart, versus one dose of Novartis MenACWY conjugate vaccine in children 2 through 10 years of age.","primaryOutcome":{"measure":"Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination","timeFrame":"One Month After Last Vaccination ( day 86)","effectByArm":[{"arm":"2 Through 5 Years (2 Vac)","deltaMin":94,"sd":null},{"arm":"2 Through 5 Years (1 Vac)","deltaMin":75,"sd":null},{"arm":"6 Through 10 Years (2 Vac)","deltaMin":89,"sd":null},{"arm":"6 Through 10 Years (1 Vac)","deltaMin":77,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":["26398741"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":179},"commonTop":["INJECTION SITE PAIN","INJECTION SITE ERYTHEMA","INJECTION SITE INDURATION","PYREXIA","MYALGIA"]}}